With saxagliptin versus placebo , serious adverse events occurred in eight versus 14 older ( incidence rate 5.7 versus 9.9 per 100 person-years ) and 49 versus 44 younger patients ( incidence rate 6.5 versus 6.6 per 100 person-years ) .